Edition:
United States

XOMA Corp (XOMA.OQ)

XOMA.OQ on NASDAQ Stock Exchange Global Market

5.26USD
17 Feb 2017
Change (% chg)

$0.11 (+2.14%)
Prev Close
$5.15
Open
$5.12
Day's High
$5.29
Day's Low
$5.12
Volume
8,206
Avg. Vol
23,780
52-wk High
$22.80
52-wk Low
$3.99

XOMA.OQ

Chart for XOMA.OQ

About

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA... (more)

Overall

Beta: 3.64
Market Cap(Mil.): $38.03
Shares Outstanding(Mil.): 7.23
Dividend: --
Yield (%): --

Financials

  XOMA.OQ Industry Sector
P/E (TTM): -- 47.80 29.39
EPS (TTM): -1.73 -- --
ROI: -99.20 -4.08 13.06
ROE: -- 4.84 14.19

BRIEF-Xoma Corp to sell 1.2 mln shares to Biotechnology Value Fund

* Xoma announces pricing of $25 million registered offering of common stock and convertible preferred stock

Feb 13 2017

BRIEF-Xoma established proof-of-concept for its product candidate 358 in congenital hyperinsulinism and hypoglycemia post-bariatric surgery

* Xoma Corp- Established proof-of-concept for its product candidate 358 in congenital hyperinsulinism and hypoglycemia post-bariatric surgery Source text for Eikon: Further company coverage:

Jan 31 2017

BRIEF-Xoma Q3 loss $2.08/shr

* Xoma reports third quarter 2016 achievements and financial results

Nov 09 2016

BRIEF-XOMA says regulatory body in Germany approves plan to conduct repeat-dose clinical study in congenital hyperinsulinism patients over age of 12

* Xoma announces significant step toward initiating pediatric phase 2 clinical study for XOMA 358 in children with congenital hyperinsulinism

Oct 19 2016

BRIEF-Xoma announces reverse stock split

* Board of directors then determined that split would be at a ratio of 1-for-20

Oct 14 2016

BRIEF-XOMA provides update from ongoing phase 2 XOMA 358 clinical studies

* XOMA provides update from ongoing phase 2 XOMA 358 clinical studies

Sep 15 2016

More From Around the Web

Competitors

  Price Chg
Albireo Pharma Inc (ALBO.OQ) $23.00 +0.41

Earnings vs. Estimates